Navigation Links
Cardium Reports on First Quarter 2008 Highlights and Financial Results

SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today reported recent highlights and developments, as well as financial results for its first quarter ended March 31, 2008.

Highlights and Recent Developments

-- European commercialization agreement with Euromed Medizinisch GmbH

(Euromed) for InnerCool's CoolBlue(TM) surface temperature modulation

system and RapidBlue endovascular system. Euromed, a leading

distributor of cardiology medical products will have exclusive

marketing, sales and distribution rights in Austria, Germany and

Switzerland for InnerCool's portfolio of temperature modulation


-- Australian distribution agreement with Lifehealthcare Pty Ltd., one of

Australia's leading medical device distributors and health service

providers. Under the agreement, Lifehealthcare has the exclusive

rights to market, sell and distribute InnerCool's CoolBlue and

RapidBlue temperature modulation systems in Australia and New Zealand.

-- Publication by BioMed Central (BMC) Cardiovascular Disorders

(2008, 8:7, April 10, 2008) of positive findings from a preclinical

study conducted by researchers at Lund University Hospital in Sweden

demonstrating a new and expanded benefit of early rapid cooling for the

potential treatment of acute myocardial infarction (heart attack). The

same researchers are currently recruiting patients for the RAPID-MI-ICE

(Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to

Percutaneous Coronary Intervention) clinical study, which is expected

to enroll approximately 20 patients who present within six hours of

their heart attack and require angioplasty and stent procedures.

Patients randomized to the cooling arm (hypothermia) will be infused

with one liter of iced saline in addition to endovascular cooling and

patients assigned to the normothermia arm will receive routine standard

of care without induced hypothermia. Additional information about the

study can be found at

-- Ongoing patient recruitment for the Company's Phase 3 Generx AWARE and

Phase 2b Excellarate MATRIX clinical trials. The AWARE clinical trial

is evaluating Generx as a potential treatment for myocardial ischemia

(insufficient blood flow within the heart muscle) which gives rise to

angina and is expected to enroll approximately 300 women at an

estimated 50 U.S. medical centers. Additional information about the

AWARE study can be found at

The MATRIX clinical trial is evaluating the safety and efficacy of

Excellarate for the potential treatment of non-healing diabetic foot

ulcers and is expected to enroll approximately 210 patients at up to

40 U.S. sites. Additional information about the MATRIX study can be

found at

-- Addition of Richard A. Schatz, M.D. to Cardium's Scientific Advisory

Board. Dr. Schatz is a pioneer of coronary stent technology and is

Research Director of Cardiovascular Interventions at the Heart, Lung,

and Vascular Center at Scripps Clinic in La Jolla, California.

-- Broadcast of the Science Channel's "Cool Stuff: How it Works" series

featuring the use of InnerCool's endovascular cooling system during

brain surgery at Stanford University. The segment (episode 5) is

scheduled to be rebroadcast tonight, May 9, at 8:30 p.m. and 11:30 p.m.


Financial Report

For the quarter ended March 31, 2008, the Company reported a net loss of $6.7 million, or $0.16 per share, which included research and development costs totaling $3.4 million and selling, general and administrative expenses of $3.4 million. Non-cash charges relating to stock-based compensation, depreciation and amortization for the first quarter of fiscal 2008 totaled $906,000. Total revenue for the first quarter 2008 was $646,000, compared to $309,000 for the same quarter last year. The increase in revenue was a result of an increase in InnerCool sales resulting from our expanded sales and marketing efforts. Cash and cash equivalents as of March 31, 2008 were $6.3 million.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit or view its 2007 Annual Report at

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, and its CoolBlue(TM) surface-based system, which is currently being marketed in the U.S., please visit

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, and our ability to obtain necessary funding, regulatory approvals and expected qualifications, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such devices and launch new devices will be successful or completed within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit

Cardium Therapeutics(TM), Corgentin(TM) and Generx(TM) are trademarks of
Cardium Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
trademarks of the Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM),

Accutrol(TM), CoolBlue(TM) and RapidBlue(TM)

are trademarks of InnerCool Therapies, Inc.

- Continued -

Cardium Therapeutics, Inc.

Three Months Ended

March 31,


Selected Condensed 2008 2007


Operational Results

Revenues $646,002 $309,331

Cost of goods sold (370,696) (246,565)

Gross profit 275,306 62,766

Research and development 3,372,480 3,242,866

Selling, general and

administrative 3,385,566 2,539,101

Amortization - Intangibles 197,414 207,043

Loss from operations (6,680,154) (5,926,244)

Interest income (expense), net (53,974) 86,395

Net loss $(6,734,128) $(5,839,849)

Net loss per common share - basic

and diluted $(0.16) $(0.17)

Weighted average shares outstanding

- basic and diluted 42,709,247 34,362,080

Selected Condensed March 31, December 31,

Consolidated Balance Sheet 2008 2007

(unaudited) (audited)

Cash and cash equivalents $6,300,638 $7,722,816

Accounts receivable, net 311,837 565,613

Inventories, net 1,337,870 1,037,164

Prepaid expenses and other current

assets 657,820 522,067

Property and equipment, net 1,644,416 1,650,632

Patented technology and intangibles,

net 4,568,916 4,766,330

Other long-term assets 748,023 661,067

Total assets $15,569,520 $16,925,689

Total current liabilities $5,545,073 $5,255,392

Long-term liabilities 2,849,334 3,241,992

Stockholder's equity 7,175,113 8,428,305

Total liabilities and stockholder's

equity $15,569,520 $16,925,689

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):